FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981946219> ?p ?o ?g. }

• W2981946219 abstract "Abstract Background Patients co-infected with HIV and HCV represent a unique subpopulation with specific high-risk characteristics including increased transmission efficiency of HCV, higher HCV viral load and more rapid progression of liver disease when compared with mono-infected patients. Although virologic failure is rare in the direct acting antiviral (DAA) era, we have anecdotally observed a high rate of failure in our patients who are co-infected and have cirrhosis. Our objective was to evaluate the impact of cirrhosis on co-infected patients compared with co-infection without cirrhosis and mono-infected patients with cirrhosis as it relates to cure of HCV treated with DAAs. Methods A retrospective chart review was performed. Patients from UConn Health Infectious Diseases and Gastroenterology clinics and Hartford Hospital Comprehensive Liver Center treated January 1, 2014 through December 31, 2017 were included. Patients were grouped as follows: (1) HCV/HIV coinfected without cirrhosis, (2) HCV/HIV coinfected with cirrhosis, (3) HCV infected with cirrhosis. Data were analyzed in SAS, variables were compared by chi square analysis and Fishers Exact test to determine statistical significance. Results No differences in baseline characteristics were noted (Table 1). Cirrhotic patients were 63% of the total cohort. There was no statistical difference in the rates of sustained virologic response (SVR) among the 3 groups. The overall rate of SVR was 95%. SVR for patients with cirrhosis (co- and mono-infected) was 92%. All treatment failures (n = 3) in this cohort had cirrhosis. Among the 38 cirrhotic patients, 3 (8%) had treatment experience with DAAs. In contrast, none of the non-cirrhotic patients had prior DAAs. The use of protease inhibitors or ribavirin had no impact on cure; ribavirin was evenly distributed between the two groups with cirrhosis. SVR rates were lower with genotypes 2–4 as compared with genotype 1. No immunologic or virologic factors were correlated with SVR. Conclusion We found no differences in rates of SVR in coinfected patients with or without cirrhosis. However, all treatment failures were noted in patients with cirrhosis, and cirrhotic patients tended to have treatment experience with DAAs. Whether coinfected patients with cirrhosis should be managed differently will require additional study. Disclosures All authors: No reported disclosures." @default.
• W2981946219 created "2019-11-01" @default.
• W2981946219 creator A5009290659 @default.
• W2981946219 creator A5027461280 @default.
• W2981946219 creator A5028544881 @default.
• W2981946219 creator A5051332842 @default.
• W2981946219 creator A5089017427 @default.
• W2981946219 date "2019-10-01" @default.
• W2981946219 modified "2023-09-27" @default.
• W2981946219 title "354. Efficacy of Second-Generation Direct Acting Antivirals in the Setting of HCV/HIV Co-infection and Cirrhosis: A Review of Real-World Treatment Experiences" @default.
• W2981946219 doi "https://doi.org/10.1093/ofid/ofz360.427" @default.
• W2981946219 hasPublicationYear "2019" @default.
• W2981946219 type Work @default.
• W2981946219 sameAs 2981946219 @default.
• W2981946219 citedByCount "1" @default.
• W2981946219 countsByYear W29819462192021 @default.
• W2981946219 crossrefType "journal-article" @default.
• W2981946219 hasAuthorship W2981946219A5009290659 @default.
• W2981946219 hasAuthorship W2981946219A5027461280 @default.
• W2981946219 hasAuthorship W2981946219A5028544881 @default.
• W2981946219 hasAuthorship W2981946219A5051332842 @default.
• W2981946219 hasAuthorship W2981946219A5089017427 @default.
• W2981946219 hasBestOaLocation W29819462191 @default.
• W2981946219 hasConcept C126322002 @default.
• W2981946219 hasConcept C159047783 @default.
• W2981946219 hasConcept C177713679 @default.
• W2981946219 hasConcept C2776455275 @default.
• W2981946219 hasConcept C2777214474 @default.
• W2981946219 hasConcept C3013748606 @default.
• W2981946219 hasConcept C71924100 @default.
• W2981946219 hasConceptScore W2981946219C126322002 @default.
• W2981946219 hasConceptScore W2981946219C159047783 @default.
• W2981946219 hasConceptScore W2981946219C177713679 @default.
• W2981946219 hasConceptScore W2981946219C2776455275 @default.
• W2981946219 hasConceptScore W2981946219C2777214474 @default.
• W2981946219 hasConceptScore W2981946219C3013748606 @default.
• W2981946219 hasConceptScore W2981946219C71924100 @default.
• W2981946219 hasLocation W29819462191 @default.
• W2981946219 hasLocation W29819462192 @default.
• W2981946219 hasOpenAccess W2981946219 @default.
• W2981946219 hasPrimaryLocation W29819462191 @default.
• W2981946219 hasRelatedWork W1988846321 @default.
• W2981946219 hasRelatedWork W1996609706 @default.
• W2981946219 hasRelatedWork W2013265476 @default.
• W2981946219 hasRelatedWork W2021484921 @default.
• W2981946219 hasRelatedWork W2093887245 @default.
• W2981946219 hasRelatedWork W2117048621 @default.
• W2981946219 hasRelatedWork W2131517701 @default.
• W2981946219 hasRelatedWork W2163649608 @default.
• W2981946219 hasRelatedWork W2313589268 @default.
• W2981946219 hasRelatedWork W2414521932 @default.
• W2981946219 hasRelatedWork W2417503891 @default.
• W2981946219 hasRelatedWork W2440740290 @default.
• W2981946219 hasRelatedWork W2906222391 @default.
• W2981946219 hasRelatedWork W2918141470 @default.
• W2981946219 hasRelatedWork W2990699913 @default.
• W2981946219 hasRelatedWork W3167519843 @default.
• W2981946219 hasRelatedWork W3202504393 @default.
• W2981946219 hasRelatedWork W3202697895 @default.
• W2981946219 hasRelatedWork W57837434 @default.
• W2981946219 hasRelatedWork W810662049 @default.
• W2981946219 isParatext "false" @default.
• W2981946219 isRetracted "false" @default.
• W2981946219 magId "2981946219" @default.
• W2981946219 workType "article" @default.